Effects of antiandrogens on transformation and transcription activation of wild-type and mutated (LNCaP) androgen receptors.
LNCaP cells contain androgen receptors with a mutation in the steroid binding domain (Thr 868 changed to Ala) resulting in a changed hormone specificity. Both the wild-type and mutated androgen receptors were transfected into COS cells. Transcription activation was studied in cells co-transfected with an androgen sensitive reporter (CAT) gene. The wild-type androgen receptor was activated by the agonist R1881, but the antiandrogens did not enhance transcription apart from a partial agonistic effect at high concentrations of cyproterone acetate. The mutated androgen receptor was fully activated by R1881, cyproterone acetate and hydroxyflutamide, but not by ICI 176,334. Receptor transformation to a tight nuclear binding state was studied by preparation of detergent washed nuclei and Western blotting with a specific antibody against the androgen receptor. Nuclei of COS cells transfected with wild-type receptor retained the receptor when the cells had been treated with the agonist R1881, partially retained receptors when treated with antiandrogen cyproterone acetate, but did not retain receptor when treated with hydroxyflutamide or ICI 176,334. The cells transfected with the mutated receptor additionally retained nuclear receptors after treatment with hydroxyflutamide. We conclude that each one of the three antiandrogens tested displayed different characteristics with respect to its effect on transformation and transcription activation.
Berrevoets
C A
CA
Department of Endocrinology and Reproduction, Erasmus University Rotterdam, The Netherlands.
Veldscholte
J
J
Mulder
E
E
D000230:Adenocarcinoma; D000409:Alanine; D000595:Amino Acid Sequence; D000726:Androgen Antagonists / Q000494:pharmacology*; D000813:Anilides / Q000494:pharmacology; D000818:Animals; D015153:Blotting, Western; D002460:Cell Line; D002467:Cell Nucleus / Q000378:metabolism; D015500:Chloramphenicol O-Acetyltransferase / Q000096:biosynthesis / Q000378:metabolism; D017373:Cyproterone Acetate / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005485:Flutamide / Q000031:analogs & derivatives / Q000494:pharmacology; D006801:Humans; D008297:Male; D015741:Metribolone / Q000494:pharmacology; D016297:Mutagenesis, Site-Directed; D009570:Nitriles; D017354:Point Mutation; D011471:Prostatic Neoplasms; D011944:Receptors, Androgen / Q000096:biosynthesis / Q000187:drug effects / Q000378:metabolism*; D011994:Recombinant Proteins / Q000096:biosynthesis / Q000187:drug effects / Q000378:metabolism; D013912:Threonine; D014105:Tosyl Compounds; D014158:Transcription, Genetic / Q000187:drug effects*; D014162:Transfection; D014170:Transformation, Genetic; D014407:Tumor Cells, Cultured
D000726:Androgen Antagonists; D000813:Anilides; D009570:Nitriles; D011944:Receptors, Androgen; D011994:Recombinant Proteins; D014105:Tosyl Compounds; D015741:Metribolone; D013912:Threonine; C014290:hydroxyflutamide; D017373:Cyproterone Acetate; D005485:Flutamide; C053541:bicalutamide; D015500:Chloramphenicol O-Acetyltransferase; D000409:Alanine